Dexcom Receives FDA Approval for Continuous Glucose Monitor
Dexcom has announced it has received FDA approval of a new continuous glucose monitoring system, according to a news release.
The Dexcom G4 PLATINUM system consists of three parts: a sensor, transmitter and monitor. According to the company, features include a long transmission range, small profile, LCD display, customizable alerts with specific tones and a "hypo alert" setting at 55 mg/dl.
"Improved accuracy in the critical hypoglycemic range is most important from a life-saving point of view," said Terrance H. Gregg, Dexcom CEO, in the release. "The Dexcom G4 PLATINUM fulfills the promise of CGM for people with diabetes by providing accurate and reliable real-time performance."
Dexcom is headquartered in San Diego.
Related Articles on FDA Clearances:
FDA Approves Stivarga for Metastatic Colorectal Cancer
Covidien Receives FDA Clearance for Bedside Respiratory Patient Monitoring System
Boston Scientific Receives FDA Clearance for Subcutaneous Implantable Defibrillator
© Copyright ASC COMMUNICATIONS 2012. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
Latest Articles
- Dr. Eva Liang Opens Center for Sight in Las Vegas
- EndoChoice's Fuse System Earns FDA 510(k) Clearance, Increases Adenoma Detection by 71%
- Dr. Andrew Rhim Receives AGA Digestive Cancer Award, $40k Grant
- NIAHO & DNV Healthcare Accredits Pacific Hospital of Long Beach
- The Conversion of an ASC to an HOPD – the Key Issues, the Pros and Cons and the Process
